VolitionRx Statistics
Total Valuation
VolitionRx has a market cap or net worth of $38.23 million. The enterprise value is $48.45 million.
Important Dates
The last earnings date was Thursday, November 13, 2025, after market close.
| Earnings Date | Nov 13, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
VolitionRx has 122.80 million shares outstanding. The number of shares has increased by 20.49% in one year.
| Current Share Class | 122.80M |
| Shares Outstanding | 122.80M |
| Shares Change (YoY) | +20.49% |
| Shares Change (QoQ) | +5.42% |
| Owned by Insiders (%) | 7.15% |
| Owned by Institutions (%) | 13.95% |
| Float | 91.59M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 20.30 |
| Forward PS | 4.70 |
| PB Ratio | n/a |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 32.92 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.12
| Current Ratio | 0.12 |
| Quick Ratio | 0.04 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -15.02 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -148.34% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 456.48% |
| Revenue Per Employee | $17,318 |
| Profits Per Employee | -$269,171 |
| Employee Count | 85 |
| Asset Turnover | 0.15 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -55.77% in the last 52 weeks. The beta is 1.24, so VolitionRx's price volatility has been higher than the market average.
| Beta (5Y) | 1.24 |
| 52-Week Price Change | -55.77% |
| 50-Day Moving Average | 0.47 |
| 200-Day Moving Average | 0.57 |
| Relative Strength Index (RSI) | 31.74 |
| Average Volume (20 Days) | 2,446,939 |
Short Selling Information
The latest short interest is 272,971, so 0.22% of the outstanding shares have been sold short.
| Short Interest | 272,971 |
| Short Previous Month | 335,716 |
| Short % of Shares Out | 0.22% |
| Short % of Float | 0.30% |
| Short Ratio (days to cover) | 0.28 |
Income Statement
In the last 12 months, VolitionRx had revenue of $1.47 million and -$22.88 million in losses. Loss per share was -$0.23.
| Revenue | 1.47M |
| Gross Profit | 1.47M |
| Operating Income | -22.70M |
| Pretax Income | -23.06M |
| Net Income | -22.88M |
| EBITDA | -21.65M |
| EBIT | -22.70M |
| Loss Per Share | -$0.23 |
Full Income StatementBalance Sheet
The company has $199,407 in cash and $11.26 million in debt, giving a net cash position of -$11.06 million or -$0.09 per share.
| Cash & Cash Equivalents | 199,407 |
| Total Debt | 11.26M |
| Net Cash | -11.06M |
| Net Cash Per Share | -$0.09 |
| Equity (Book Value) | -35.95M |
| Book Value Per Share | -0.32 |
| Working Capital | -10.09M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$19.62 million and capital expenditures -$151,192, giving a free cash flow of -$19.77 million.
| Operating Cash Flow | -19.62M |
| Capital Expenditures | -151,192 |
| Free Cash Flow | -19.77M |
| FCF Per Share | -$0.16 |
Full Cash Flow StatementMargins
| Gross Margin | 100.00% |
| Operating Margin | -1,542.22% |
| Pretax Margin | -1,566.41% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VolitionRx does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -20.49% |
| Shareholder Yield | -20.49% |
| Earnings Yield | -61.19% |
| FCF Yield | -52.88% |
Analyst Forecast
The average price target for VolitionRx is $3.17, which is 918.31% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $3.17 |
| Price Target Difference | 918.31% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 172.68% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
VolitionRx has an Altman Z-Score of -65.94 and a Piotroski F-Score of 2. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -65.94 |
| Piotroski F-Score | 2 |
